Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 21, 2024 10:51am

174 Views

Post# 36274735

RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

October 21, 2024 - Sanofi has officially struck a deal to sell a 50% controlling stake in consumer healthcare unit Opella to a private equity firm, valuing the new standalone company at €16 billion (US$17.3 billion).

https://www.biospace.com/business/sanofi-seals-deal-with-private-equity-firm-for-50-stake-in-consumer-healthcare-unit

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing